TITLE

UCB GETS POSITIVE RESULTS FROM TWO CIMIZIA PHASE III STUDIES

PUB. DATE
February 2007
SOURCE
Worldwide Biotech;Feb2007, Vol. 19 Issue 2, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that UCB got positive results for signs and symptoms from two Cimzia phase III studies in the treatment of rheumatoid arthritis. UCB has also received a complete response letter from the U.S. Food and Drug Administration requesting additional information and clarification on data submitted in its Biologics License Application for the approval of Cimzia in Crohn's disease.
ACCESSION #
23758069

 

Related Articles

  • COMPANY SPOTLIGHT - UCB.  // PharmaWatch: Biotechnology;Jun2008, Vol. 7 Issue 6, p22 

    The article presents a corporate profile of biopharmaceutical firm UCB Pharma. UCB is a global firm involved in the research, development and marketing of pharmaceutical and biotechnology products in the areas of central nervous system (CNS) disorders and allergy/respiratory diseases. Its...

  • FDA ACCEPTS XYREM SNDA FOR REVIEW.  // Biotech Business;May2005, Vol. 18 Issue 5, p2 

    Reports on the decision of the U.S. Food and Drug Administration to accept for filing the Supplemental New Drug Application (sNDA) of Orphan Medical Inc. for its Xyrem(R) (sodium oxybate) oral solution. Marketing strategy for Xyrem; Target diseases for treatment using Xyrem; Fee received by...

  • Genentech/Biogen Idec: Rituxan further expands its options.  // PharmaWatch: Biotechnology;Apr2006, Vol. 5 Issue 4, p12 

    The article reports that the Rituxan drug developed by Genentech Inc. and Biogen Idec Inc. has gained another approval from the U.S. Food and Drugs Administration (FDA), making it the first selective B-cell therapy to be approved in rheumatoid arthritis in 2006. The FDA approval is for Rituxan...

  • Genentech/Biogen Idec: Rituxan further expands its options.  // PharmaWatch: Monthly Review;Apr2006, Vol. 5 Issue 4, p29 

    The article reports that the U.S. Food and Drug Administration approved the drug Rituxan from Genentech Inc. and Biogen Idec Inc. to help treat rheumatoid arthritis (RA). The approval allows the companies to market Rituxan to be used with methotrexate for the treatment of signs and symptoms of...

  • American Academy of Neurology.  // BioWorld Today;4/15/2010, Vol. 21 Issue 72, p4 

    The article reports that UCB Pharma Inc. is negotiating with the U.S. Food and Drug Administration (FDA) to make Neupro, a rotigotine transdermal system, to be available to patients with early state Parkinson's disease as soon as possible.

  • FDA Actions. Elliott, William T. // Clinical Cardiology Alert;Jun2009 Pharmacology Watch, p2 

    The article presents an update on U.S. Food and Drug Administration (FDA) actions in 2009. A morning after pill called Plan B from Duramed Pharmaceuticals will be available to women age 17 and older without a prescription following a court order directing the FDA to evaluate clinical data to...

  • Warning issued on RA drug. Maudlin, Robert K. // Modern Medicine;Jun99, Vol. 67 Issue 6, p51 

    Focuses on the advice of the United States Food and Drug Administration regarding the use of etanercept, an approved treatment for moderate to severe rheumatoid arthritis. Warning on the label when the drug was originally approved; Advice for physicians when considering prescribing etanercept...

  • Rheumatoid arthritis drugs show promise.  // Mayo Clinic Health Letter;Jan1999, Vol. 17 Issue 1, p4 

    Broadcasts the approval of the Food and Drug Administration for two drugs, etanercept and leflunomide for the treatment of rheumatoid arthritis. Drug composition; Dosage.

  • Dateline Washington. Coorsh, Richard // Consumers' Research Magazine;Dec98, Vol. 81 Issue 12, p6 

    Introduces Enbrel, a genetically engineered drug approved by the United States Food and Drug Administration for the treatment of rheumatoid arthritis.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics